Suchergebnisse - "Yan, Lufeng"

PubPharm (26)

1

Rhamnan sulfate reduces atherosclerotic plaque formation and vascular inflammation

enthalten in: Biomaterials | 2022

von Patil, N. | Gómez-Hernández, A. | Zhang, F. | +14

2

Proline-Rich Region II (PRR2) Plays an Important Role in Tau-Glycan Interaction : An NMR Study

enthalten in: Biomolecules | 2022

von Murray, A. | Yan, L. | Gibson, J. | +7

3

Rhamnan Sulfate Reduces Atherosclerotic Plaque Formation and Vascular Inflammation

enthalten in: bioRxiv.org | 2022

von Patil, N. | Gómez-Hernández, A. | Zhang, F. | +14

4

Mixture of fucosylated chondroitin sulfate oligosaccharides and method for rapidly producing the same

enthalten in: Europäisches Patentamt | 2021

von CHEN SHIGUO | YAN LUFENG | WANG DANLI | +3

5

Heparan sulfates from bat and human lung and their binding to the spike protein of SARS-CoV-2 virus

enthalten in: Carbohydrate polymers | 2021

von Yan, L. | Song, Y. | Xia, K. | +12

6

Heparosan Chain Characterization : Sequential Depolymerization of E. Coli K5 Heparosan by a Bacterial Eliminase Heparin Lyase III and a Bacterial Hydrolase Heparanase Bp to Prepare Defined Oligomers

enthalten in: Biotechnology journal | 2021

von Datta, P. | Yan, L. | Awofiranye, A. | +2

7

EGCG binds intrinsically disordered N-terminal domain of p53 and disrupts p53-MDM2 interaction

enthalten in: Nature communications | 2021

von Zhao, J. | Blayney, A. | Liu, X. | +16

8

Oral Administration of Fucosylated Chondroitin Sulfate Oligomers in Gastro-Resistant Microcapsules Exhibits a Safe Antithrombotic Activity

enthalten in: Thrombosis and haemostasis | 2021

von Yan, L. | Zhu, M. | Wang, D. | +6

9

A Revised Structure for the Glycolipid Terminus of Escherichia coli K5 Heparosan Capsular Polysaccharide

enthalten in: Biomolecules | 2020

von Yan, L. | Fu, L. | Xia, K. | +4

10

Chemical O-sulfation of N-sulfoheparosan : a route to rare N-sulfo-3-O-sulfoglucosamine and 2-O-sulfoglucuronic acid

enthalten in: Glycoconjugate journal | 2020

von Yan, L. | Brodfueher, P. | Fu, L. | +4